High androgen receptor splice variant 7 (ARV7) mRNA or protein expression level in CTCs from patients with advanced prostate cancer is associated with resistance to therapy with enzalutamide and abiraterone to target androgen receptors [171]. This evidence concerns the gene AR and prostate cancer.